COMP <GO>
RLMD vs CYPH // EV/EBITDA & P/E VALUATION
Relmada Therapeutics Inc. (NASDAQ) VS. Cypherpunk Technologies Inc. (NASDAQ) • 15-METRIC TALLY: RLMD 2
— CYPH 3
■ METRIC PARITY
LAST: $3.44 (+2.69%) • MKT CAP: $366.9M
valuation
—
LAST: $3.31 (+2.16%) • MKT CAP: $356.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. CYPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RLMD | CYPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -23.30% | -11.70 | CYPH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.48% | -12.31% | -0.17 | CYPH | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | CYPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 51.0 | +1.94 | RLMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 66.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $366.9M | $356.7M | $10.2M | RLMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RLMD REV | CYPH REV | RLMD GROSS % | CYPH GROSS % | RLMD FCF | CYPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$45.8M | -$43.9M |
| FY 2024 | $0 | $0 | — | — | -$51.8M | -$60.3M |
| FY 2023 | — | $0 | — | — | — | -$43.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
CYPH // BETA —